Dr. Chih-Ming Su is the Director of Breast Health Care Center, Shuang Ho Hospital, Taipei Medical University, Taiwan.
Dr. Chih-Ming Su’s feedback highlights the critical need for more sensitive and reliable blood-based monitoring tools in the management of breast cancer. The EG-Breast Blood Test-P1, with its innovative approach to detecting aberrant methylation in cfDNA, has the potential to meet this need and become an invaluable tool in improving long-term outcomes for breast cancer patients.
Clinical and Market Demand
Dr. Chih-Ming Su provided positive feedback regarding the potential impact of the EG-Breast Blood Test-P1. He emphasized that in clinical settings where the cost of medical testing is high, such as in Europe and the United States, there would be significant clinical demand and economic benefits for a test like the EG-Breast Blood Test-P1. The ability to offer patients a more sensitive and reliable method of monitoring breast cancer progression could improve clinical outcomes and provide substantial value in these markets.
Current Clinical Data
Recent clinical data demonstrate that traditional blood markers such as CA15-3 and CEA, commonly used for monitoring breast cancer, have limited sensitivity—around 50%—in predicting disease progression. This means that approximately half of the patients who experience recurrence or metastasis may not be detected early enough using these markers.
The EG-Breast Blood Test-P1, however, shows over 90% sensitivity and holds significant promise in improving early detection rates. When patients also undergo analysis of aberrantly methylated cfDNA, and if the EG-Breast Blood Test-P1 detects abnormal methylation signals, it can alert both physicians and patients to consider earlier imaging studies or shorten follow-up intervals. This proactive approach could potentially lead to earlier detection of recurrence and overall improvement in patient survival rates.